Salta al contenuto principale
Passa alla visualizzazione normale.



  • Autori: Siracusano, S.; Abrate, A.; Di Maida, F.; Giacalone, N.; Cangemi, A.; Moschini, M.; Colombo, R.; Simonato, A.; Serretta, V.
  • Anno di pubblicazione: 2016
  • Tipologia: Proceedings (TIPOLOGIA NON ATTIVA)
  • OA Link:


Introduction/Aim: To reduce the diagnosis of indolent prostate cancer (PCa) and to prevent progression of aggressive tumors are two important targets in urological oncology. Prostate specific antigen (PSA) demonstrates low accuracy in the early detection of high risk tumors. There is some evidence in literature that obese patients and/or patients affected by metabolic syndrome (MS) might be at higher risk for biologically aggressive PCa characterized by Gleason patterns 4 or 5. The aim of our study was to investigate the correlation between the body mass index (BMI) class, serum levels of adiponectin, leptin and metalloproteinase 3 (MMP-3) that are biomarkers related to MS and the detection at biopsy of Gleason patterns 4 and 5. Materials and Methods: Consecutive patients undergoing prostate biopsy for PSA levels ≥4 ng/ml and/or positive digital rectal examination were included. Patients were classified in relation to BMI. Blood samples for the evaluation of adiponectin, leptin and MMP-3 were collected. A 12-core transrectal prostate biopsy was performed. Serum adiponectin, leptin and MMP-3 were measured using “Human Leptin Instant ELISA”, “Human Adiponectin ELISA”, “Human MMP-3 ELISA” kits, respectively. Statistical analysis was performed to relate the plasmatic levels of the abovementioned biomarkers to the presence of Gleason patterns 4 and 5 at biopsy. Results: Fifty-six patients were enrolled. Median serum levels of leptin, adiponectin and MMP-3 were 0.829 ng/ml, 1.72 ng/ml and 1.767 ng/ml, respectively. In relation to BMI class, the plasmatic levels of leptin and MMP- 3 were higher in obese (p=0.02) and in normal-weight patients (p=0.02), respectively. No statistically significant difference was detected in serum levels of leptin (p=0.18), adiponectin (p=0.68) and MMP-3 (p=0.49) between the 24 patients (42.8%) with diagnosis of PCa and the 30 patients (53.7%) with a negative biopsy. Comparing the levels of biomarkers in 11/24 patients (45.8%) with Gleason 6 (3+3) and in 13/24 (54.2%) showing Gleason patterns 4 and 5 at biopsy, again, no statistically significant difference in leptin (p=0.4), adiponectin (p=0.6) and MMP-3 (p=0.5) levels was found. Conclusion: In our preliminary study, we found increased plasmatic levels of leptin and MMP-3 in obese and normal-weight patients undergoing prostate biopsy, respectively. The significance of this finding, in patients with an elevated PSA, is uncertain. On the other hand, no other statistical difference was found between BMI, plasmatic levels of leptin, adiponectin, MMP-3 and detection of an aggressive Gleason pattern at biopsy.